Intravenous NAD+ infusion studies
- Reported quantity
- 500–750 mg per infusion
- Frequency
- Daily to weekly
- Study duration
- Single infusions to 6-day courses
Infusion over 4–6 hours is standard; faster rates are poorly tolerated in the reported work.
Protocols · Longevity
NAD+: literature-reported ranges
Direct NAD+ infusion has a thin trial literature; the substantial evidence sits with its precursors, nicotinamide riboside and nicotinamide mononucleotide, which have multiple randomised human studies.
Read this first
Every figure on this page is a range reported in published literature or in a publicly documented study protocol. It is a record of what researchers used, not a recommendation, a therapeutic protocol, or advice. Peptide Intel Hub is an independent publication, sells nothing, and describes these compounds as in-vitro research reagents only.
Compound at a glance
- Class
- Nicotinamide adenine dinucleotide coenzyme
- Reported half-life
- Rapidly metabolised; intravenous infusions run over hours by necessity
- Routes used in the literature
- Intravenous infusion, subcutaneous and oral (as precursors) in published work
- Also written as
- —
What the published studies reported
Each row below describes one body of work. The model and population are part of the figure — a rodent per-kilogram quantity and a human trial quantity are not comparable.
Nicotinamide riboside randomised trials
- Reported quantity
- 250–1000 mg orally per day
- Frequency
- Once or twice daily
- Study duration
- 6–12 weeks
Blood NAD+ elevation is reliably reported; downstream clinical endpoints much less so.
Nicotinamide mononucleotide trials
- Reported quantity
- 250–900 mg orally per day
- Frequency
- Once daily
- Study duration
- 8–12 weeks
Trials are mostly small, short and heterogeneous in their endpoints.
Dosage chart
These figures match the published chart for this compound on peptidedosages.com, including the reconstitution volume, resulting concentration, insulin-syringe units and the staged schedule. Educational reference only — not instructions, and not medical advice.
NAD+ · 1000 mg Vial
NAD+ is dosed at 50 mg–100 mg daily via subcutaneous injection in educational protocols. A 1000 mg vial reconstituted with bacteriostatic water yields about 333.3 mg/mL. This information is for research and educational use only.
- Reconstitute
- Add 3.0 mL bacteriostatic water → 333.3 mg/mL concentration.
- Typical daily range
- 50–100 mg once daily subcutaneously (gradual titration from lower doses).
- Easy measuring
- At 333.3 mg/mL, 1 unit = 0.01 mL = 3.33 mg on a U‑100 insulin syringe.
- Storage
- Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) for up to 14 days; protect from light and avoid freeze–thaw cycles.
Standard / Gradual Titration Approach (3 mL = 333.3 mg/mL)
| Week | Daily Dose (mg) | Units (per injection) (mL) |
|---|---|---|
| Week 1 | 50 mg | 15 units (0.15 mL) |
| Week 2 | 75 mg | 22.5 units (0.225 mL) |
| Weeks 3–8 | 100 mg | 30 units (0.30 mL) |
| Weeks 9–12 | 100 mg | 30 units (0.30 mL) |
| Weeks 13–16 | 100 mg | 30 units (0.30 mL) |
Mixed with 3 ml of bacteriostatic water
The same arithmetic for every vial size NAD+ is supplied in, using a fixed 3 ml of bacteriostatic water. One unit on a U-100 insulin syringe is 0.01 ml, so the unit column below is simply the volume that carries the reported amount. Educational arithmetic only — not instructions, and not medical advice.
NAD+ · 3 ml bacteriostatic water
| Vial size | Concentration | Per 1 unit | 50 mg = | 100 mg = |
|---|---|---|---|---|
| 500 mg | 166.67 mg/ml | 1,667 mcg | 30 units | 60 units |
| 1000 mg | 333.33 mg/ml | 3,333 mcg | 15 units | 30 units |
Unit columns use the range reported for this compound (50 mg–100 mg). Only the vial sizes this compound is actually supplied in are shown, and every figure assumes exactly 3 ml of bacteriostatic water. For any other volume, use the reconstitution calculator.
Reconstitution maths
Injectable NAD+ is usually supplied as a solution (commonly 100 mg/mL) or as a powder for dilution into a saline bag for infusion.
Open the reconstitution calculatorHow to read these figures
- Infusion rate, not just quantity, determines tolerability — chest tightness and nausea are rate-related.
- Precursor evidence is not evidence for direct infusion; they are separate literatures.
- Raising a blood biomarker is not the same as changing a clinical outcome, and the trials mostly show the former.
Sources and citations
These are the published records the figures on this page are drawn from. Each one describes what researchers administered, in which model or population, and over what period. Quantities reported in a study are specific to that study's design and are not transferable guidance.
- [1]Randomized, placebo-controlled, pilot clinical study evaluating acute Niagen+ IV and NAD+ IV in healthy adults
Hawkins J, Idoine R, Kwon J, Shao A, et al. · medRxiv (preprint) · 2024 · DOI 10.1101/2024.06.06.24308565
Healthy adults received a single intravenous infusion of NAD+ or a nicotinamide riboside-based IV formulation at specified doses to assess tolerability and pharmacokinetics.
View the record - [2]Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men
Irie J, Inagaki E, Fujita M, et al. · Endocr J · 2019 · PMID 31685720
Healthy men received single oral doses of nicotinamide mononucleotide (NMN) at 100, 250, or 500 mg to evaluate safety and NAD+ precursor metabolite levels.
View the record - [3]The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial
Yi L, Maier AB, Tao R, et al. · GeroScience · 2022 · PMID 36482258
Middle-aged adults received oral NMN at 300, 600, or 900 mg/day for 60 days in a dose-dependent randomized controlled trial.
View the record
Search the databases yourself
Read the NAD+ research briefOther longevity compounds
CartalaxSynthetic tripeptide (Ala-Glu-Asp) bioregulatorEpithalonSynthetic tetrapeptide (Ala-Glu-Asp-Gly)FOXO4-DRIFOXO4-p53 interaction-disrupting retro-inverso peptideGlutathioneEndogenous tripeptide antioxidant (Glu-Cys-Gly)
All research protocolsPeptide Intel Hub is an independent publication and has no affiliation, ownership or commercial relationship with the suppliers listed. We sell nothing and take no payments — links are editorial references only.